Table 3.
DC-based immunotherapy.
| Authors | Antigen | DC | Adjuvant | Patients | Duration of PFS/RFS | Results |
|---|---|---|---|---|---|---|
| Oosterwijk-Wakka | Auto lysate | Auto imDC | KLH/IL-2 | 12 | — | 8 SD, 4 PD |
| Marten | Auto lysate | Auto mDC | KLH | 15 | — | 1 PR, 7 SD, 7 PD |
| Holtl | Auto & Allo lysate | Auto mDC | KLH | 27 | 20.4 mo | 2 CR, 1 PR, 7 SD, 17 PD |
| Azuma | Auto lysate | Auto imDC | KLH | 3 | — | 1 NC, 2 PD |
| Marten | DC/auto tumor fusion | Allo mDC | — | 12 | — | 4 SD, 8 PD |
| Su | tumor RNA | Auto imDC | — | 10 | — | not evaluated |
| Gitliz | Auto lysate | Auto imDC | — | 12 | — | 1 PR, 3 SD, 8 PD |
| Barbuto | DC/auto tumor fusion | Allo mDC | — | 19 | 5.7 mo | 30 R, 14 SD, 2 PD |
| Avigan | DC/auto tumor fusion | Auto imDC | KLH | 13 | 4.2 mo | 5 SD, 8 PD |
| Pandha | Allo lysate | Auto imDC | KLH | 5 | — | 2 SD |
| Arroyo | Auto lysate | Auto mDC | KLH | 5 | 9.6 mo (5–16) | 3 SD |
| Holtl | Auto & Allo TuLy | Allo mDC | KLH/Cy | 20 | 22.3 mo | 2 MR, 3 SD, 15 PD |
| Wierecky | MUC-1 peptide | Auto mDC | PADRE | 20 | 10.8 mo (4–24) | 1 CR, 2 MR, 2 PR, 5 SD, 10 PD |
| Bleumer | CA9 peptide | Auto mDC | KLH CA9 class II peptide | 6 | — | 6 PD |
| Wei | DC/auto tumor fusion | Auto mDC | IL-2 | 10 | 7 mo (5–12) | 1 PR, 3 SD, 6 PD |
| Matsumoto | Auto lysate | Auto mDC | KLH | 3 | — | 1 SD, 2 PD |
| Kim | Auto lysate | Auto mDC | KLH | 9 | 5.2 mo | 1 PR, 5 SD, 3 PD |
| Berntsen | Lysate or surviving and telomerase peptides | Auto mDC | IL-2 | 27 | 2.7 mo | 13 SD, 14 PD |
| Tatsugami | Auto TuLy | Auto mDC | IFN-α | 7 | 7.8 mo | 5 SD, 2 PD |
| Zbou | DC/auto tumor fusion | Allo mDC | — | 10 | — | 1 PR, 6 SD, 3 PD |
Cy: cyclophosphamide, PADRE: pan-MHC class II binding peptide, Auto mDC: autologous mature DC, Allo imDC: allogeneic immature DC CR: complete response, PR: partial response, MR: mixed response, SD: stable disease, OR: objective response, PD: progressive disease, PFS: progression-free survival, RFS: recurrence-free survival.